BioSpace News Archive

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that the Company will report its fourth quarter and full year 2022 financial results and provide a corporate update on Tuesday, March 14, 2023.

Intelligent Bio Solutions Inc. today announced the pricing of its previously announced underwritten public offering of 569,560 shares of common stock and warrants to purchase up to 170,868 shares of its common stock at a combined public offering price of $3.90 per share of common stock.

Inhibikase Therapeutics, Inc. today announced the U.S. Food and Drug Administration (“FDA” or “Agency”) has lifted the full Clinical Hold on IkT-148009, the Company’s c-Abl inhibitor, in Multiple System Atrophy (MSA) allowing the Company to proceed with its plans for a future Phase 2 clinical trial in MSA.

Citius Pharmaceuticals, Inc. today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California.

PreciseDx today announced that it will present a poster showcasing the development and validation of its AI-enabled hematoxylin and eosin (H&E) image analysis grading and phenotyping Platform to predict risk of early-stage breast cancer recurrence.

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research.

Molecure S.A. (“Molecure”: WSE: MOC) announces today that the first patient has been dosed in a Phase I trial evaluating OATD-02 as a monotherapy in cancer patients with advanced solid tumors.

Investor partner Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and investor in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. (“Inretio”)

Vetter has recently become a participant of the UN Global Compact Network (UN GC). The globally operating Contract Development and Manufacturing Organization (CDMO) is one of the pioneers in the industry regarding responsible, sustainable, and transparent business practices.

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced Dr. Damon Broyles, MD, the VP of Clinical Innovation at Mercy Technology Services (MTS), the technical support arm of Mercy Healthcare, has joined Cardio Diagnostics as a strategic advisor.